Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.

@article{Chen2015UpregulationOP,
  title={Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.},
  author={Nan Chen and Wenfeng Fang and Jianhua Zhan and Shaodong Hong and Yanna Tang and Shiyang Kang and Yaxiong Zhang and Xiaobo He and Ting Zhou and Tao Qin and Yan Huang and Xianping Yi and Li Zhang},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2015},
  volume={10 6},
  pages={910-23}
}
INTRODUCTION Epidermal growth factor receptor (EGFR) mutation status was reported to be associated with programmed death-ligand 1 (PD-L1) expression. However, the molecular mechanism of PD-L1 regulation by EGFR activation and the potential clinical significance of blocking PD-1/PD-L1 in EGFR-mutant non-small-cell lung cancer (NSCLC) treated with EGFR tyrosine kinase inhibitors (TKIs) were largely unknown. METHODS Western blot, real-time polymerase chain reaction, immunofluorescence, and flow… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 13 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 96 extracted citations

Regulation of PD-L1: a novel role of pro-survival signalling in cancer.

Annals of oncology : official journal of the European Society for Medical Oncology • 2016
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…